Our study provides evidence both in MPN patients and in new human UT-7 cell lines that the impact of the JAK2V617F mutation on the production by mutated cells of inflammation cytokines and receptors concerns essentially IL-1β, IL-1Rα and IP-10. The gene discussed is CXCL10; the disease is myeloproliferative disorder.